[go: up one dir, main page]

PE20040836A1 - Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc) - Google Patents

Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc)

Info

Publication number
PE20040836A1
PE20040836A1 PE2003001162A PE2003001162A PE20040836A1 PE 20040836 A1 PE20040836 A1 PE 20040836A1 PE 2003001162 A PE2003001162 A PE 2003001162A PE 2003001162 A PE2003001162 A PE 2003001162A PE 20040836 A1 PE20040836 A1 PE 20040836A1
Authority
PE
Peru
Prior art keywords
pyrimidine nucleoside
hepatitis
inhibitors
ilmethyl
azido
Prior art date
Application number
PE2003001162A
Other languages
English (en)
Inventor
Joseph Armstrong Martin
Keshab Sarma
David Bernard Smith
Mark Smith
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32329161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20040836(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20040836A1 publication Critical patent/PE20040836A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS NUCLEOSIDO DE PIRIMIDINA DE FORMULA I, EN DONDE R1 Y R2 SON H, COR5, C(=O)OR5, C(=O)SR5, ENTRE OTROS; R3 Y R4 SON H, COR5, C(=O)OR5, C(=O)SR5, ENTRE OTROS; O R3 Y R4 TOMADOS JUNTOS SON CH2, C(CH3)2 o CHPh; R5 ES ALQUILO C1-C18 RAMIFICADO O NO, ALQUENILO C1-C18 RAMIFICADO O NO, ALQUINILO C1-C18 RAMIFICADO O NO, HALOALQUILO C1-C18, ENTRE OTROS; CON LA CONDICION DE QUE AL MENOS UNO DE R1, R2, R3 o R4 ES OTRO QUE HIDROGENO. ESTOS COMPUESTOS PUEDEN PRESENTARSE EN FORMA DE HIDRATOS, SOLVATOS, CLATRATOS Y SALES DE ADICION ACIDA. SON COMPUESTOS PREFERIDOS: ACETATO DE (2R, 3S, 4R, 5R)-3,4-DIACETOXI-5-(4-ACETILAMINO-2-OXO-2H-PIRIMIDIN-1-IL)-2-AZIDO-TETRAHIDRO-FURAN-2-ILMETILO; PROPIONATO DE (2R, 3S, 4R, 5R)-2-AZIDO-5-(2-OXO-4-PROPIONILAMINO-2H-PIRIMIDIN-1-IL)-3,4-BIS-PROPIONILOXI-TETRAHIDRO-FURAN-2-ILMETILO; BUTIRATO DE (2R, 3S, 4R, 5R)-2-AZIDO-5-(4-BUTIRILAMINO-2-OXO-2H-PIRIMIDIN-1-IL)-3,4-BIS-BUTIRILOXI-TETRAHIDRO-FURAN-2-ILMETILO; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCESO PARA LA PREPARACION DE UN NUCLEOSIDO DE PIRIMIDINA 1',3',4'-TRIACILO DE UN NUCLEOSIDO N,1',3',4'-TETRAACILPIRIMIDINA. ESTOS COMPUESTOS SON INHIBIDORES DE LA REPLICACION DE RNA DEL REPLICON VIRUS DE LA HEPATIS C Y SON UTILES PARA TRATAR ENFERMEDADES MEDIADAS POR EL VIRUS DE LA HEPATITIS C
PE2003001162A 2002-11-19 2003-11-17 Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc) PE20040836A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42744702P 2002-11-19 2002-11-19
US48397003P 2003-07-01 2003-07-01

Publications (1)

Publication Number Publication Date
PE20040836A1 true PE20040836A1 (es) 2004-11-25

Family

ID=32329161

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001162A PE20040836A1 (es) 2002-11-19 2003-11-17 Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc)

Country Status (29)

Country Link
US (1) US6846810B2 (es)
EP (1) EP1565481B1 (es)
JP (1) JP4362450B2 (es)
KR (1) KR100676662B1 (es)
AR (1) AR042192A1 (es)
AT (1) ATE335755T1 (es)
AU (1) AU2003288064B2 (es)
BR (1) BR0316407A (es)
CA (1) CA2504846C (es)
CO (1) CO5550501A2 (es)
CY (1) CY1106207T1 (es)
DE (1) DE60307503T2 (es)
DK (1) DK1565481T3 (es)
ES (1) ES2270136T3 (es)
HR (1) HRP20050417B1 (es)
IL (1) IL168266A (es)
JO (1) JO2403B1 (es)
MX (1) MXPA05005282A (es)
MY (1) MY136229A (es)
NO (1) NO330424B1 (es)
NZ (1) NZ539644A (es)
PA (1) PA8588501A1 (es)
PE (1) PE20040836A1 (es)
PL (1) PL210967B1 (es)
PT (1) PT1565481E (es)
RU (1) RU2327701C2 (es)
TW (1) TWI332507B (es)
UY (1) UY28084A1 (es)
WO (1) WO2004046159A1 (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
DE60325709D1 (de) 2002-04-09 2009-02-26 Flamel Tech Sa Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
DE60323474D1 (de) * 2002-04-09 2008-10-23 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CN1678326A (zh) * 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
NZ537662A (en) 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
DK1576138T3 (en) 2002-11-15 2017-05-01 Idenix Pharmaceuticals Llc 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION
PL377287A1 (pl) 2002-12-12 2006-01-23 Idenix (Cayman) Limited Sposób wytwarzania 2'-rozgałęzionych nukleozydów
EP1575971A4 (en) * 2002-12-23 2008-03-05 Idenix Cayman Ltd PROCESS FOR THE PREPARATION OF 3-NUCLEOSIDE PRODRUGS
WO2005000864A1 (en) * 2003-06-19 2005-01-06 F. Hoffmann-La Roche Ag Processes for preparing 4’azido nucleoside derivatives
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
JP2008510748A (ja) * 2004-08-23 2008-04-10 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４’−アジド−ヌクレオシド
JP4516863B2 (ja) * 2005-03-11 2010-08-04 株式会社ケンウッド 音声合成装置、音声合成方法及びプログラム
US20070166378A1 (en) * 2005-06-09 2007-07-19 Flamel Technologies, Inc. Oral ribavirin pharmaceutical compositions
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
CN101268092B (zh) * 2005-09-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 核苷的选择性o-酰基化
EP1957510A1 (en) * 2005-12-09 2008-08-20 F.Hoffmann-La Roche Ag Antiviral nucleosides
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
CN101330906B (zh) * 2005-12-14 2010-12-29 弗·哈夫曼-拉罗切有限公司 Hcv前药制剂
US7781576B2 (en) * 2005-12-23 2010-08-24 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
CA2647276A1 (en) * 2006-04-04 2007-10-11 F. Hoffmann-La Roche Ag 3',5'-di-o-acylated nucleosides for hcv treatment
WO2008045419A1 (en) * 2006-10-10 2008-04-17 Pharmasset, Inc. Preparation of nucleosides ribofuranosyl pyrimidines
CN101979397B (zh) 2006-10-10 2013-11-06 美迪维尔公司 Hcv核苷类抑制剂
MX2009004900A (es) 2006-11-09 2009-05-19 Hoffmann La Roche Arilamidas sustituidas por tiazol u oxazol.
US8501933B2 (en) 2006-11-09 2013-08-06 Roche Palo Alto Llc Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists
JP2010512365A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー ４’−アジドシチジン誘導体の製造方法
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
ATE525068T1 (de) 2007-02-28 2011-10-15 Conatus Pharmaceuticals Inc Verfahren zur behandlung von chronischer viraler hepatitis c mithilfe von ro 113-0830
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
ES2377760T3 (es) 2007-03-29 2012-03-30 F. Hoffmann-La Roche Ag Composición farmacéutica y proceso
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CL2008003511A1 (es) * 2007-11-29 2010-02-19 Metabasis Therapeutics Inc Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EP2234989B1 (en) * 2007-12-17 2014-08-13 F. Hoffmann-La Roche AG Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
JP5301561B2 (ja) * 2007-12-17 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー 新規なピラゾール置換アリールアミド
EP2234981B1 (en) 2007-12-17 2016-03-30 F. Hoffmann-La Roche AG Novel imidazole-substituted arylamides
BRPI0821266B8 (pt) * 2007-12-17 2023-02-07 Hoffmann La Roche Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009277172B2 (en) * 2008-07-02 2014-05-29 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2010014276A1 (en) * 2008-07-31 2010-02-04 3M Innovative Properties Company Azide compositions and methods of making and using thereof
EP2379745A1 (en) * 2008-12-18 2011-10-26 F. Hoffmann-La Roche AG Biomarkers for hcv treatment response
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
SI2389164T1 (sl) * 2009-01-21 2014-12-31 F. Hoffmann-La Roche Ag Farmacevtski sestavki, obsegajoäśi predzdravilo inhibitorja hcv polimeraze
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
AU2010220374A1 (en) 2009-03-06 2011-09-01 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
CA2754654A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel oxazolone and pyrrolidinone-substituted arylamides
SG177301A1 (en) * 2009-06-22 2012-02-28 Hoffmann La Roche Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists
CA2764956A1 (en) * 2009-06-22 2010-12-29 F. Hoffmann-La Roche Ag Novel biphenyl and phenyl-pyridine amides
WO2010149598A2 (en) 2009-06-24 2010-12-29 F. Hoffmann-La Roche Ag Heterocyclic antiviral compound
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011033045A1 (en) 2009-09-21 2011-03-24 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
JP2013511489A (ja) 2009-11-21 2013-04-04 エフ．ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
TW201136942A (en) 2009-12-18 2011-11-01 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis C virus inhibitors
PL2528930T3 (pl) * 2010-01-28 2014-03-31 Riboscience Llc 4`-azydonukleozydy jako związki przeciw hcv
CA2794671C (en) 2010-03-31 2018-05-01 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
EP2552203B1 (en) 2010-04-01 2017-03-22 Idenix Pharmaceuticals LLC. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2012012776A1 (en) 2010-07-22 2012-01-26 Gilead Sciences, Inc. Methods and compounds for treating paramyxoviridae virus infections
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP2646453A1 (en) 2010-11-30 2013-10-09 Gilead Pharmasset LLC Compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
CN103842369A (zh) 2011-03-31 2014-06-04 埃迪尼克斯医药公司 用于治疗病毒感染的化合物和药物组合物
US9403863B2 (en) 2011-09-12 2016-08-02 Idenix Pharmaceuticals Llc Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
CA2847892A1 (en) 2011-09-12 2013-03-21 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
KR20190075142A (ko) 2011-09-16 2019-06-28 길리애드 파마셋 엘엘씨 Hcv 치료 방법
WO2013056046A1 (en) 2011-10-14 2013-04-18 Idenix Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
MX2014006479A (es) 2011-11-30 2015-01-22 Univ Emory Inhibidores antivirales de la janus cinasa utiles en el tratamiento o prevencion de infecciones retrovirales y otras infecciones virales.
US20130217644A1 (en) 2012-02-13 2013-08-22 Idenix Pharmaceuticals, Inc. Pharmaceutical Compositions of 2'-C-Methyl-Guanosine, 5'-[2[(3-Hydroxy-2,2-Dimethyl-1-Oxopropyl)Thio]Ethyl N-(Phenylmethyl)Phosphoramidate]
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
MX355708B (es) 2012-05-22 2018-04-27 Idenix Pharmaceuticals Llc Compuestos de d-aminoacidos para enfermedades del higado.
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
TW201408688A (zh) 2012-05-25 2014-03-01 Janssen R & D Ireland 尿嘧啶基螺氧環丁烷（ｓｐｉｒｏｏｘｅｔａｎｅ）核苷類
EP2900682A1 (en) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
AP2015008384A0 (en) 2012-10-08 2015-04-30 Univ Montpellier Ct Nat De La Rech Scient 2'-Chloro nucleoside analogs for hcv infection
US20140112886A1 (en) 2012-10-19 2014-04-24 Idenix Pharmaceuticals, Inc. Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
WO2014078436A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-alanine ester of sp-nucleoside analog
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
HUE047777T2 (hu) 2013-01-31 2020-05-28 Gilead Pharmasset Llc Két vírusellenes vegyület kombinációs készítménye
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
WO2014137926A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. 3'-deoxy nucleosides for the treatment of hcv
US20140271547A1 (en) 2013-03-13 2014-09-18 Idenix Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
WO2014165542A1 (en) 2013-04-01 2014-10-09 Idenix Pharmaceuticals, Inc. 2',4'-fluoro nucleosides for the treatment of hcv
WO2014197578A1 (en) 2013-06-05 2014-12-11 Idenix Pharmaceuticals, Inc. 1',4'-thio nucleosides for the treatment of hcv
TW201542578A (zh) 2013-06-26 2015-11-16 Alios Biopharma Inc 經取代之核苷、核苷酸及其類似物
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
EP3650014B1 (en) 2013-08-27 2021-10-06 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015066370A1 (en) 2013-11-01 2015-05-07 Idenix Pharmaceuticals, Inc. D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
PE20170698A1 (es) * 2014-09-26 2017-06-05 Riboscience Llc Derivados de nucleosidos sustituidos con 4'-vinilo como inhibidores de la replicacion del arn del virus respiratorio sincitial
SG11201705069YA (en) 2014-12-26 2017-07-28 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111788196A (zh) 2018-01-09 2020-10-16 配体药物公司 缩醛化合物及其治疗用途
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
CN115362004B (zh) 2020-04-06 2026-01-09 吉利德科学公司 1’-氰基取代的碳核苷类似物的吸入制剂
WO2021243157A1 (en) 2020-05-29 2021-12-02 Gilead Sciences, Inc. Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
WO2022008025A1 (en) * 2020-07-05 2022-01-13 Since & Technology Development Fund Authority 2-hydroxyiminopyrimidine nucleosides and derivitives and antiviral uses thereto
PT4204421T (pt) 2020-08-27 2024-06-25 Gilead Sciences Inc Compostos e métodos para o tratamento de infeções virais
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
TWI867455B (zh) 2022-03-02 2024-12-21 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998807A (en) 1972-03-03 1976-12-21 Syntex (U.S.A.) Inc. Arabinofuranosyl cytosines and methods of making
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
SE8801729D0 (sv) 1988-05-06 1988-05-06 Astra Ab Purine derivatives for use in therapy
US5449664A (en) * 1988-11-21 1995-09-12 Syntex (U.S.A.) Inc. Antiviral agents
ATE123285T1 (de) 1988-12-19 1995-06-15 Wellcome Found Antivirale pyrimidin- und purinverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische präparate.
US5216142A (en) 1989-04-17 1993-06-01 Efamol Holdings Plc Anti-virals
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
DE4207363A1 (de) * 1992-03-04 1993-09-09 Max Delbrueck Centrum Antivirale nucleosidanaloga, ihre herstellung und ihre pharmazeutische verwendung
GB9307043D0 (en) 1993-04-05 1993-05-26 Norsk Hydro As Chemical compounds
DE4311801A1 (de) 1993-04-09 1994-10-13 Hoechst Ag Neue Carbonsäureester von 2-Amino-7-(1,3-dihydroxy-2-propoxymethyl)purin, deren Herstellung sowie deren Verwendung
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
TR200101085T2 (tr) 1998-10-16 2001-08-21 Schering Corporation Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
SI20976A (sl) 1999-12-23 2003-02-28 Icn Pharmaceuticals, Inc. Sestavki in postopki za L-nukleozide, L-nukleotide in njihove analoge
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) * 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
SI1355916T1 (sl) * 2001-01-22 2007-04-30 Merck & Co Inc Nukleozidni derivati kot inhibitorji RNA-odvisne RNA virusne polimeraze
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives

Also Published As

Publication number Publication date
ES2270136T3 (es) 2007-04-01
DK1565481T3 (da) 2006-12-18
MXPA05005282A (es) 2005-07-25
WO2004046159A1 (en) 2004-06-03
PA8588501A1 (es) 2004-05-26
WO2004046159A8 (en) 2005-06-30
IL168266A (en) 2010-11-30
TWI332507B (en) 2010-11-01
ATE335755T1 (de) 2006-09-15
HRP20050417B1 (hr) 2013-11-08
JP2006519169A (ja) 2006-08-24
KR20050083909A (ko) 2005-08-26
PL210967B1 (pl) 2012-03-30
RU2327701C2 (ru) 2008-06-27
CY1106207T1 (el) 2011-06-08
DE60307503T2 (de) 2007-08-16
NO330424B1 (no) 2011-04-11
JO2403B1 (en) 2007-06-17
US6846810B2 (en) 2005-01-25
HRP20050417A2 (en) 2006-06-30
AU2003288064B2 (en) 2008-10-09
EP1565481A1 (en) 2005-08-24
AR042192A1 (es) 2005-06-15
UY28084A1 (es) 2004-05-31
NO20052304L (no) 2005-06-23
JP4362450B2 (ja) 2009-11-11
RU2005119633A (ru) 2006-01-27
PT1565481E (pt) 2006-12-29
EP1565481B1 (en) 2006-08-09
CO5550501A2 (es) 2005-08-31
PL377632A1 (pl) 2006-02-06
TW200426154A (en) 2004-12-01
MY136229A (en) 2008-08-29
DE60307503D1 (de) 2006-09-21
KR100676662B1 (ko) 2007-02-01
AU2003288064A1 (en) 2004-06-15
NZ539644A (en) 2007-01-26
US20040121980A1 (en) 2004-06-24
CA2504846A1 (en) 2004-06-03
BR0316407A (pt) 2005-10-11
CA2504846C (en) 2012-01-03

Similar Documents

Publication Publication Date Title
PE20040836A1 (es) Derivados de nucleosidos de pirimidina como inhibidores de la replicacion de rna del virus de la hepatitis c (vhc)
PE20071131A1 (es) Nucleosidos antivirales (2r)2'-deoxi-2-metil-2-fluoro-citidina
PE20080704A1 (es) Inhibidores ns5b del virus hepatitis c de indolobenzazepina fusionados a ciclopropilo
CN1942186B (zh) 吡咯烷化合物
ES2524119T3 (es) Furazanobencimidazoles como profármacos para tratar enfermedades neoplásicas o autoinmunes
PE20070751A1 (es) Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20020707A1 (es) Compuestos tripeptidicos como inhibidores de la proteasa ns3 del virus de hepatitis c
PE20031012A1 (es) Compuesto inhibidor de la hepatitis c
PE20070210A1 (es) Compuestos macrociclicos como inhibidores del virus de hepatitis c
PE20000949A1 (es) Tripeptidos inhibidores de la hepatitis c
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
PE20080418A1 (es) Compuestos y composiciones como moduladores de la via de hedgehog
AR061008A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20061439A1 (es) DERIVADOS DE 2-AMIDO-6-AMINO-8-OXO-PURINA COMO MODULADORES DEL RECEPTOR Toll (TLR)
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
PE20070343A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
AR041009A1 (es) Compuestos heterociclicos nitrogenados que presentan actividad inhibitoria contra la integrasa del vih
PE20080144A1 (es) Compuestos de tetrahidropiridotienopirimidina con actividad antiproliferativa
UY27333A1 (es) Nucleótidos 4` sustituidos
PE20090630A1 (es) Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
CO5580815A2 (es) Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed